CA-AIRSPACE
17.3.2021 14:02:14 CET | Business Wire | Press release
Airspace today announced it has been granted a U.S. patent for its optimized logistics management system as of March 2. The patent covers the system, method, and computer programming of the logistical and graphical presentation of the most optimal path for transporting goods from a pickup location to a destination location at lowest transit cost and minimal risk.
Airspace leverages its patented technology and world-class team to provide certainty in the time-critical logistics space through unrivaled speed and shipment transparency . The routing operation is arguably the most important step in the logistical transportation process because the optimal route saves both money and time, while enabling customers to monitor progress along the route provides transparency.
“This technology is a game-changer for the supply chain and logistics industry,” said Ryan Rusnak , co-founder and CTO at Airspace.
Airspace’s technology calculates the best routes in less than a second instead of the typical 30 minutes or more that are standard in the time-critical shipping industry. The router generates a time and space expectation of where each order should be at any given time, which is checked via distributed sensors. Even if an expected flight is canceled, the technology immediately establishes a new plan and tracks it. Airspace provides automated notifications in real time to the customer instead of having to wait for personal contact calls, generating leading indicators rather than lagging ones.
“Our transparency with this process creates trust and confidence for both shippers and receivers,” said Rusnak. “We believe we are setting a new standard for the logistics industry.”
Logistical challenges are difficult because most shipments don’t start at an airport; they start at an arbitrary place such as a lab, warehouse, hospital, and so on. Airspace’s technology takes into consideration ground travel time as well, allowing for traffic to and from nearby airports to the final destination. This technology can provide the difference between life and death, for example, in the case of organs for transplant.
“If you choose a route that doesn’t give the driver enough time, you set the shipment up for failure. Create a route that is too conservative, and you risk losing the last flight that gets the package there when it’s needed,” said Nick Bulcao , co-founder and CEO of Airspace. “This is the extremely difficult optimization challenge that only Airspace can solve today, using our proprietary software and artificial intelligence. We are extremely proud of our inventors and pleased that our technology can make a real difference.”
Airspace, which recently closed its Series C funding round , is positioned to provide the best customer experience for clients while relentlessly analyzing data to address ongoing needs. It continues to grow, focused on making international expansion as seamless as possible by blending operations and R&D for the benefit of the industry.
About Airspace
Airspace, founded in 2016, has grown to be a leading global delivery network for time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through its people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints, Airspace surfaces more information than any other provider, increasing trust and transparency of the supply chain. To learn more, visit www.airspace.com . Follow Airspace: Twitter , Facebook , Instagram and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005325/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
